As first reported by Tech.eu, French healthtech startup DESKi has raised $6 million in a seed round led by Racine² (Serena & makesense), with participation from BNP Paribas Développement, Épopée Gestion, Good Only Ventures, Better Angle, and NACo. The funding will drive the U.S. and European expansion of DESKi’s flagship product, HeartFocus—an AI-powered cardiac ultrasound solution designed to democratize access to heart disease diagnostics.
Source: heartfocus.ai.
A solution for a global cardiac care gap
Founded by brothers Bertrand and Olivier Moal, DESKi addresses a critical challenge: the global shortage of trained specialists capable of performing echocardiograms. HeartFocus is FDA-cleared and clinically validated, offering real-time AI guidance that enables even first-time users to conduct accurate cardiac scans after minimal training. This innovation could revolutionize early detection in cardiology—particularly in remote or underserved settings where expert care is often out of reach.
Technology built for scale and impact
HeartFocus uses proprietary AI trained on over 10 million data points, allowing it to guide users through image capture with precision and confidence. The tool has already earned recognition from the French Ministry of Health through the France 2030 award and integrates seamlessly into existing digital health platforms. By making high-quality diagnostics accessible outside of specialized clinics, DESKi offers a scalable solution at a time when healthcare systems are struggling to meet growing cardiovascular care demands.
Moving from proof to global deployment
With this new funding, DESKi is transitioning from clinical validation to commercial rollout, bringing its life-saving technology to broader populations across Europe and the U.S. The company’s expansion marks a key step in redefining frontline care for one of the world’s deadliest conditions.
DESKi’s HeartFocus is poised to transform the cardiac diagnostics landscape by empowering a broader range of healthcare providers to detect heart disease early. With its AI-driven, user-friendly approach and a solid foundation of regulatory approval and clinical evidence, the company is ready to scale its impact globally—offering a new, accessible standard for cardiac care.
